Pixium Vision Appoints James A. Reinstein to Board of Directors

Regulatory News:

Pixium Vision (Paris:PIX) (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, today announced the appointment of James A. Reinstein to its Board of Directors. Mr. Reinstein joins as an independent board member. Mr. Reinstein was until recently President and Chief Executive Officer at Aptus Endosystems Inc. until its sale to Medtronic. Aptus Endosystems was a medical device company engaged in developing and manufacturing advanced technology for treatment of aortic disease.

Bernard Gilly, Chairman of Pixium Vision said: "Our primary objective is to finish the development of IRIS^® and bring it to the market. As Pixium Vision embarks into this new chapter, James’s extensive industry knowledge and international commercial, marketing and operational experience will be an asset to the company. We are thrilled to have him join our Board, and look forward to benefiting from his valuable perspective and leadership.”

James A. Reinstein previously held the position of Senior Vice President and Chief Commercial Officer for Cyberonics, a neurostimulation company focused on the treatment of epilepsy and depression. At Cyberonics, he led a commercial turn around by growing revenues from approximately $100 million in 2007 to over $200 million within four years. Mr. Reinstein joined Cyberonics after a 17-year career with Boston Scientific Corp., where he held general management and commercial leadership positions in Europe, Latin America and Asia. He built strong teams within those operations with solid competencies in sales, marketing, government affairs, reimbursement, logistics and finance. After earning a Bachelor’s Degree in Business Administration from the Terry College of Business at the University of Georgia in Athens, Mr. Reinstein spent four years in sales and sales management roles with Procter & Gamble. Mr. Reinstein also completed General Management studies at INSEAD in Fontainebleau, France.

About Pixium Vision (www.pixium-vision.com)

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. Pixium Vision’s VRS are composed of various high-tech elements, associated with a surgical intervention as well as a rehabilitation period. These systems aim to ultimately provide blind patients with vision approaching that of a normal healthy eye.

Clinical trials are currently underway with the VRS IRIS^® in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. The results of these studies will be used to apply for CE mark. Approval of IRIS^® is expected in 2015.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.

Pixium Vision is listed on Euronext (Compartment C) in Paris.
ISIN: FR0011950641; ticker: PIX

IRIS^® is a trademark of Pixium-Vision SA

Disclaimer

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward-looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company’s Documents de Base filed with the AMF under number I. 14-030 on May 12, 2014 and Chapter 2 "Risk Factors related to the Offer" in the prospectus, which can be found on the websites of the AMF - AMF (www.amf-france.org) and Pixium Vision (www.pixium-vision.com).

View source version on businesswire.com: http://www.businesswire.com/news/home/20150623006663/en/